LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.

Product information

CAS Number: 107889-32-7

Molecular Weight: 319.46

Formula: C18H25NO2S

Chemical Name: (5E)-5-[(3,5-di-tert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazolidin-4-one

Smiles: CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C1/SCNC/1=O

InChiKey: BUDGLLLMROWLOB-NTEUORMPSA-N

InChi: InChI=1S/C18H25NO2S/c1-17(2,3)12-7-11(9-14-16(21)19-10-22-14)8-13(15(12)20)18(4,5)6/h7-9,20H,10H2,1-6H3,(H,19,21)/b14-9+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

LY178002 inhibits the generation of LTB4, PLA2 and FCO with IC50s of 0.1, 6.3 and 4.2 μM .

In Vivo:

LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81%, and inhibits bone damage in rats. The minimum effective dose for LY178002 is 10 mg/kg p.o. In the established FCA model LY178002 at 50 mg/kg p.o. inhibits the uninjected paw swelling by 75%.

Products are for research use only. Not for human use.